Tag: Cftr modulator

Approved by the FDA on December 20, 2024, Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is a once-daily, triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for patients aged 6 and older who have specific genetic mutations. This medication builds upon previous advancements to offer a more convenient dosing schedule and enhanced efficacy for eligible individuals.

More than 90% of cystic fibrosis (CF) patients in the United States are eligible for treatment with Trikafta. So, what class of drug is Trikafta? It belongs to a revolutionary class of medications known as cystic fibrosis transmembrane conductance regulator (CFTR) modulators, specifically a triple-combination therapy, that directly targets the underlying genetic cause of the disease.

Over 90% of people with cystic fibrosis may be eligible for a new treatment called Alyftrek, which was approved by the FDA in December 2024 [1.4.2]. When considering this medication, a primary question is: how much does Alyftrek cost? The annual list price is approximately $370,269 [1.3.4, 1.3.6].

In a major advancement for cystic fibrosis (CF) care, the FDA approved Alyftrek in late 2024, and it became widely available in 2025, offering a significant upgrade for eligible patients. The question on many minds is, **what is the new CF drug 2025?** This once-daily triple-combination therapy simplifies treatment and continues the trend of targeted therapies that address the underlying cause of the disease.